Evidence map›Paper›PMID 39915634›Full record

ArticleNPJ precision oncology2025

Bio-primed machine learning to enhance discovery of relevant biomarkers.

David M Henke, Alexander Renwick, Joseph R Zoeller, Jitendra K Meena, Nicholas J Neill, Elizabeth A Bowling, Kristen L Meerbrey, Thomas F Westbrook, Lukas M Simon

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

David M HenkeMolecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, 77030, USA.
Alexander RenwickDepartment of Statistics, Rice University, Houston, TX, 77030, USA.
Joseph R ZoellerMedical Scientist Training Program, Baylor College of Medicine, Houston, TX, 77030, USA.
Jitendra K MeenaVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, 77030, USA.
Nicholas J NeillVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, 77030, USA.
Elizabeth A BowlingVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, 77030, USA.
Kristen L MeerbreyVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, 77030, USA.
Thomas F WestbrookVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, 77030, USA.
Lukas M SimonVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, 77030, USA. lukas.simon@bcm.edu.

Funding

MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALSU01CA214125 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ANURAG, MEENAKSHI, CARR, STEVEN A · 2017 to 2021
$7.0M
Training Interdisciplinary Pharmacology ScientistsT32GM120011 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI DESSAUER, CARMEN W. · 2016 to 2020
$1.0M
NCI NIH HHS U01 CA214125NIH HHS T32GM120011NIH HHS U01CA214125Susan G. Komen PDF17487931U.S. Department of Defense 1W81XWH-18-1-0573Welch Foundation Q-0007
6 · The paper itself

Abstract

Precision medicine relies on identifying reliable biomarkers for gene dependencies to tailor individualized therapeutic strategies. The advent of high-throughput technologies presents unprecedented opportunities to explore molecular disease mechanisms but also challenges due to high dimensionality and collinearity among features. Traditional statistical methods often fall short in this context, necessitating novel computational approaches that harness the full potential of big data in bioinformatics. Here, we introduce a novel machine learning approach extending the Least Absolute Shrinkage and Selection Operator (LASSO) regression framework to incorporate biological knowledge, such as protein-protein interaction databases, into the regularization process. This bio-primed approach prioritizes variables that are both statistically significant and biologically relevant. Applying our method to multiple dependency datasets, we identified biomarkers which traditional methods overlooked. Our biologically informed LASSO method effectively identifies relevant biomarkers from high-dimensional collinear data, bridging the gap between statistical rigor and biological insight. This method holds promise for advancing personalized medicine by uncovering novel therapeutic targets and understanding the complex interplay of genetic and molecular factors in disease.

Identifiers

PMID39915634
PMCPMC11802771

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.